TY - T1的阿奇霉素的成本效益减少控制哮喘发作的JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02436 -2020欧元六世- 57 - 2 SP - 2002436 AU -奥尼尔,Ciaran AU -吉布森,Peter g . AU -希尼利亚姆•g . AU - Upham John w . AU -杨,伊恩·a . AU -雷诺兹,保罗•n . AU -霍奇桑德拉AU -詹金斯,克里斯汀·r . AU -彼得斯,马修盟——标志着家伙b . AU -詹姆斯,艾伦•l . AU -辛普森Jodie L. Y1 - 201/02/01 UR - //www.qdcxjkg.com/content/57/2/2002436.abstract N2 -添加阿奇霉素(AZM)可显著降低成人持续性不受控制哮喘患者的病情加重。本研究的目的是评估附加AZM在医疗保健和社会成本方面的成本效益。AMAZES试验将420名参与者随机分配到AZM组或安慰剂组。在治疗期间测量了医疗保健使用和哮喘加重情况。医疗保健使用包括所有处方药和医疗保健接触。抗微生物药物耐药性(AMR)的成本是根据总消费量和已公布的成本估计数估算的。避免恶化的价值基于已发表的参考文献。两组之间的成本差异与一系列净货币效益估计中恶化的差异有关。社会成本包括生产力损失、非处方药物、类固醇引起的发病率和抗微生物药物耐药性成本。增加AZM导致医疗成本(平均(95% CI))减少，包括住院夜(433.70澳元(48.59-818.81澳元)或260.22欧元(29.15-491.29欧元)，计划外医疗访问(20.25澳元(5.23-35.27澳元)或12.15欧元(3.14-21.16欧元))，抗生素成本(14.88澳元(7.55-22.21澳元)或8.93欧元(4.53-13.33欧元)和口服皮质类固醇成本(4.73澳元(0.82-8.64澳元)或2.84欧元(0.49-5.18欧元); all p<0.05. Overall healthcare and societal costs were lower (AUD 77.30 (EUR 46.38) and AUD 256.22 (EUR 153.73) respectively) albeit not statistically significant. The net monetary benefit of add-on AZM was estimated to be AUD 2072.30 (95% CI AUD 1348.55–2805.23) or (EUR 1243.38 (EUR 809.13–1683.14) assuming a willingness to pay per exacerbation avoided of AUD 2651 (EUR 1590.60). Irrespective of the sensitivity analysis applied, the net monetary benefit for total, moderate and severe exacerbations remained positive and significant.Add-on AZM therapy in poorly controlled asthma was a cost-effective therapy. Costs associated with AMR did not influence estimated cost-effectiveness.Add-on AZM in the treatment of poorly controlled persistent asthma is cost-effective. It is associated with a positive net monetary benefit when costs including those associated with antimicrobial resistance are considered. https://bit.ly/31aZ3fi ER -